Table 5.
Detailed immunological, histopathological and clinical information of individual patients included.
| P. | group | LsdL class I (+/-/np) | LsdL class II (+/-/np) | DSA class I | MFI | DSA class II | MFI | DSA: p.e./dn | Days between biopsy/diagnosis and trans-plantation | Biopsy type | C4d | C3d glom | C3d ptc | C5b-9 glom | C5b-9 ptc |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | aABMR | + | + | B62 | 6000 | dn | 751 | InB | C4d+ | 3 | 0 | 1 | 1 | ||
| 2 | aABMR | + | + | A23 | 16000 | DR53 DQ2 | 40000 | dn | 3095 | InB | C4d+ | 3 | 1 | 1 | 0 |
| 3 | aABMR | - | + | DQ2 DQ5 | 9000 | 440 | InB | C4d+ | 2 | 0 | 1 | 1 | |||
| 4 | aABMR | – | + | DQ2 | 3000 | dn | 1485 | InB | C4d- | ms | 0 | 1 | 0 | ||
| 5 | aABMR | - | + | DQ6 | 10000 | dn | 3453 | InB | C4d+ | 3 | 1 | 1 | 1 | ||
| 6 | aABMR | + | + | B38, B51 | 40000 | DR8 DR13 DR52 | 12000 | dn | 5 | InB | C4d+ | 3 | 3 | 1 | 0 |
| 7 | aABMR | - | + | 5625 | InB | C4d+ | 1 | 1 | 1 | 3 | |||||
| 8 | aABMR | + | – | B62 | 10000 | dn | 2256 | InB | C4d+ | 3 | 1 | 1 | 0 | ||
| 9 | aABMR | - | + | DQ1 | 20000 | dn | 3016 | InB | C4d+ | ms | ms | ms | ms | ||
| 10 | aABMR | + | – | A2 | 3000 | dn | 1006 | InB | C4d+ | 3 | 1 | 1 | 0 | ||
| 11 | aABMR | - | + | DQ6 DQ8 DR52 | 27900 | dn | 1499 | InB | C4d+ | 3 | 1 | 1 | 1 | ||
| 12 | aABMR | – | – | 3297 | InB | C4d+ | ms | 1 | ms | 1 | |||||
| 13 | aABMR | + | + | DR12 DR52 DQ9 | 14500 | dn | 7 | InB | C4d+ | 3 | 1 | ms | 0 | ||
| 14 | aABMR | + | + | A24,Cw9,Cw10 | 8000 | DR13 DR52 DQ8 | 3500 | p.e. | 20 | InB | C4d+ | 3 | 0 | 1 | 0 |
| 15 | aABMR | + | + | DQ2 | 16000 | 969 | InB | C4d+ | 1 | 1 | 1 | 1 | |||
| 16 | aABMR | + | + | A24 | 2500 | DR13 DR52 | 6000 | p.e. | 141 | InB | C4d+ | 3 | 1 | 1 | 0 |
| 17 | aABMR | + | + | DQ6 | 1000 | dn | 531 | InB | C4d+ | 2 | 3 | 1 | 2 | ||
| 18 | aTCMR | + | + | 6 | InB | C4d- | 1 | 0 | 0 | 0 | |||||
| 19 | aTCMR | - | - | 1921 | InB | C4d+ | 1 | 0 | ms | ms | |||||
| 20 | aTCMR | – | – | 154 | InB | C4d- | 1 | 0 | 0 | 0 | |||||
| 21 | aTCMR | - | - | 883 | InB | C4d- | 1 | 0 | 1 | 0 | |||||
| 22 | aTCMR | – | – | 305 | InB | C4d- | ms | ms | ms | ms | |||||
| 23 | aTCMR | + | + | 451 | InB | C4d- | 1 | 1 | ms | 1 | |||||
| 24 | aTCMR | – | – | 18 | InB | C4d- | ms | ms | ms | ms | |||||
| 25 | aTCMR | - | - | 1111 | InB | C4d- | 3 | 0 | 1 | 0 | |||||
| 26 | aTCMR | – | – | 15 | InB | C4d- | 1 | 0 | 1 | 1 | |||||
| 27 | aTCMR | - | - | 77 | InB | C4d- | 1 | 1 | 0 | 0 | |||||
| 28 | aTCMR | – | – | 55 | InB | C4d- | 0 | 1 | 0 | 2 | |||||
| 29 | aTCMR | - | - | 142 | InB | C4d- | 3 | 1 | 0 | 0 | |||||
| 30 | aTCMR | + | + | DQ7 | 20000 | dn | 531 | InB | C4d- | 1 | 0 | 1 | 0 | ||
| 31 | aTCMR | np | np | 192 | InB | C4d- | 0 | 1 | 0 | 1 | |||||
| 32 | aTCMR | – | + | DR13 | 3000 | p.e. | 585 | InB | C4d- | 1 | 0 | 0 | 0 | ||
| 33 | aTCMR | - | + | DQ2 DR53 | 4000 | dn | 117 | InB | C4d- | 2 | 1 | 0 | 1 | ||
| 34 | aTCMR | – | – | 11 | InB | C4d- | 2 | 0 | 1 | 0 | |||||
| 35 | aTCMR | - | - | 18 | InB | C4d- | 0 | 0 | ms | 0 | |||||
| 36 | NR | np | np | 387 | PB | C4d- | 1 | 1 | 1 | 0 | |||||
| 37 | NR | np | np | 166 | PB | C4d- | 2 | 0 | 1 | 1 | |||||
| 38 | NR | np | np | 357 | PB | C4d- | 0 | 0 | 1 | 0 | |||||
| 39 | NR | np | np | 380 | PB | C4d- | ms | ms | 1 | 0 | |||||
| 40 | NR | – | – | 372 | PB | C4d- | 0 | 0 | 0 | 0 | |||||
| 41 | NR | np | np | 379 | PB | C4d- | ms | ms | 1 | 0 | |||||
| 42 | NR | np | np | 392 | PB | C4d- | 1 | 0 | 1 | 0 | |||||
| 43 | NR | - | - | 358 | PB | C4d- | 1 | 1 | 1 | 0 | |||||
| 44 | NR | – | – | 388 | PB | C4d- | 1 | 0 | 0 | 0 | |||||
| 45 | NR | np | np | 180 | PB | C4d- | ms | 0 | ms | 1 | |||||
| 46 | NR | np | np | 169 | PB | C4d- | 1 | 0 | 1 | 1 | |||||
| 47 | NR | np | np | 379 | PB | C4d- | ms | ms | 1 | 0 | |||||
| 48 | NR | np | np | 193 | PB | C4d- | ms | 1 | ms | 0 | |||||
| 49 | NR | np | np | 190 | PB | C4d- | ms | ms | ms | ms | |||||
| 50 | NR | np | np | 178 | PB | C4d- | 1 | 0 | ms | 0 |
Histopathological diagnosis and Banff scores are based on Banff’19 classification. Anti-HLA-Abs are screened for in serum with LifeScreen de Luxe (LsdL). C4d deposition are displayed dichotomously in this table, indicating presence (+) or absence (-) in biopsy specimen. Complement factors C3d and C5b-9 were scored semiquantitatively. C3d and C5b-9 scores range from 0 to 4, indicating lack of any deposit, weak deposition (≤25%), moderate deposition (≤50%), substantial deposition (≤75%), and intense deposition (>75%) (25). p., patient; DSA, human-leucocyte antigen donor-specific antibody; MFI, mean fluorescence intensity; p.e., pre- existing; dn, deNovo; ABMR, Antibody-mediated rejection; aTCMR, acute T-cell mediated rejection; NR, non-rejection; IndB, biopsy due to clinical indication; protocol biopsy; +, positive test; -, negative test; np, test was not performed; ms, missing sample.